TCM
TBPH icon

Tang Capital Management’s Theravance Biopharma TBPH Stock Holding History

Tang Capital Management’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-351,252
Closed -$6.57M – 72
2025
Q4 		$6.57M Buy
351,252
+86,944
+33% +$1.44M 0.32% 52
2025
Q3 		$3.86M Hold
264,308
– – 0.15% 101
2025
Q2 		$2.92M Buy
264,308
+1,412
+0.5% +$13.7K 0.15% 107
2025
Q1 		$2.35M Hold
262,896
– – 0.13% 106
2024
Q4 		$2.47M Hold
262,896
– – 0.16% 99
2024
Q3 		$2.12M Buy
+262,896
New +$2.28M 0.15% 98

Other funds holding TBPH

MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ICM
Irenic Capital Management New York $2.08B AUM 19.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Tang Capital Management's TBPH Position: Q1 2026 in Review

Tang Capital Management sold out of Theravance Biopharma (TBPH) in Q1 2026, closing a stake of 351,252 shares — an estimated $6.57M sold.

Tang Capital Management first reported a position in TBPH in Q3 2024 and held it in 6 quarters. The position peaked at $6.57M in Q4 2025. 174 funds tracked by Wall St. Rank hold TBPH as of Q1 2026.

  • Tang Capital Management reported no remaining Theravance Biopharma position as of Q1 2026 after selling out during the quarter.
  • Tang Capital Management sold 351,252 Theravance Biopharma shares in Q1 2026, an estimated $6.57M.
  • Tang Capital Management first reported a position in Theravance Biopharma in Q3 2024 and held it in 6 quarters.
  • Tang Capital Management's Theravance Biopharma position peaked at $6.57M in Q4 2025.
  • 174 funds tracked by Wall St. Rank held Theravance Biopharma as of Q1 2026.

Based on Tang Capital Management's 13F filing for Q1 2026, filed 15 May 2026.